Previous studies have shown that a history of testicular cancer increases the risk for developing prostate cancer. A new study presented at the 2015 Genitourinary Cancers Symposium shows, for the first time ever, a link between a history of testicular cancer and an increased likelihood of intermediate- and high-risk prostate cancer sometime in the future.
Experts are hopeful that the field of prostate cancer will soon be catching up to breast cancer and some other tumor types with regard to genomic markers.
Active surveillance is sometimes used as management strategy in patients with intermediate-risk prostate cancer, especially in older, sicker men with short life expectancy. A new study validates the use of active surveillance for men with low-risk prostate cancer but provides sobering data regarding this type of management for those with intermediate-risk prostate cancer.
Adding Radiation to Antiandrogen Hormone Therapy Extends Survival in Patients with High-Risk Prostate Cancer
San Francisco, CA —Radiation added to hormone therapy with antiandrogens extended cancer-specific survival, as well as overall survival, when used as the primary treatment of patients with locally advanced or high-risk prostate cancer. In the Scandinavian Prostate Cancer Group VII study, 10- and 15-year survival improved by more than 50% in patients who received radiation plus hormone therapy versus hormone therapy alone, according to an updated analysis presented at the 2014 ASCO Genitourinary Cancers Symposium.
San Francisco, CA—Enzalutamide (Xtandi) prolonged survival and delayed radiographic progression of disease in men who had not received chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). The complete results of the phase 3 PREVAIL trial were presented at the 2014 Genitourinary Cancers Symposium.
The Cancer Genome Atlas Project: Newly Discovered Molecular Alterations in Bladder Cancer May Lead to Novel Therapies
San Francisco, CA—Researchers have successfully completed a comprehensive characterization of molecular alterations in muscle-invasive urothelial bladder carcinoma as part of The Cancer Genome Atlas (TCGA) project.
San Francisco, CA—Penile cancer is not very common in the United States, but it can be potentially fatal and appropriate treatment is crucial. A new, large population-based study showed that the management of patients with penile cancer in the United States is often not in line with current guidelines, including the 2013 National Comprehensive Cancer Network (NCCN) clinical guidelines for the management of penile cancer.
Results 1 - 7 of 7